-
Product Insights
NewAlcohol Addiction – Drugs In Development, 2024
Empower your strategies with our Alcohol Dependence – Drugs In Development, 2024 report and make more profitable business decisions. Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking, and violent behavior. Risk factors include age, family history, and depression or other mental health problems. The Alcohol Dependence drugs in development market research report provide comprehensive information on the therapeutics under development for Alcohol Dependence, complete with...
-
Product Insights
NewAttention Deficit Hyperactivity Disorder (ADHD) – Drugs In Development, 2024
Empower your strategies with our Attention Deficit Hyperactivity Disorder (ADHD) – Drugs In Development, 2024 report and make more profitable business decisions. Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity, and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination, and inability to sustain attention on tasks or activities. Treatment includes analeptics. The Attention Deficit Hyperactivity Disorder (ADHD) drugs in development market research report provide comprehensive information on the therapeutics under development for Attention...
-
Product Insights
NewGouty Arthritis (Gout) – Drugs In Development, 2024
Empower your strategies with our Gouty Arthritis (Gout) – Drugs In Development, 2024 report and make more profitable business decisions. Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in the blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area, and joint redness. Risk factors include obesity, high alcohol...
-
Product Insights
NewKlebsiella Infections – Drugs In Development, 2024
Empower your strategies with our Klebsiella Infections – Drugs In Development, 2024 report and make more profitable business decisions. Klebsiella infections are caused by bacteria of the genus Klebsiella, with K. pneumoniae being the most common species associated with human infections. These bacteria are part of the normal flora in the human digestive tract and respiratory system but can cause various infections, especially in individuals with weakened immune systems or underlying health conditions. Klebsiella infections can manifest in different parts of...
-
Product Insights
NewNatural Killer Cell Lymphomas – Drugs In Development, 2024
Empower your strategies with our Natural Killer Cell Lymphomas – Drugs In Development, 2024 report and make more profitable business decisions. Natural killer (NK) cell lymphomas are a rare and aggressive type of lymphoma arising from a subset of white blood cells called natural killer cells, which are part of the body's immune system. These lymphomas can affect various organs and tissues in the body. NK cell lymphomas are categorized into two main types. Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is...
-
Product Insights
NewRectal Cancer – Drugs In Development, 2024
Empower your strategies with our Rectal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources, and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as...
-
Product Insights
NewThalassemia – Drugs In Development, 2024
Empower your strategies with our Thalassemia – Drugs In Development, 2024 report and make more profitable business decisions. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite, and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant. The Thalassemia drugs in development market research report provide comprehensive information on the therapeutics under development for...
-
Product Insights
NewAngioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2024
Empower your strategies with our Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2024 report and make more profitable business decisions. Angioimmunoblastic T-cell lymphoma (AITL), previously known as immunoblastic lymphadenopathy, is a rare and aggressive form of peripheral T-cell lymphoma that originates from mature T cells in the immune system. AITL typically affects individuals in late adulthood and often presents with generalized symptoms including enlarged lymph nodes, fever, night sweats, weight loss, skin rashes, and an increased risk of infections....
-
Product Insights
NewLupus Nephritis – Drugs In Development, 2024
Empower your strategies with our Lupus Nephritis – Drugs In Development, 2024 report and make more profitable business decisions. Lupus nephritis is a severe complication of systemic lupus erythematosus (SLE), an autoimmune disease that affects various organs, tissues, and systems within the body. Lupus nephritis specifically involves inflammation of the kidneys, leading to kidney damage and impaired kidney function. In systSLE, the body's immune system mistakenly attacks its own tissues and organs, including the kidneys, causing inflammation. Not all individuals with...